Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia

Michael A Moso; Joe Sasadeusz; Catherine O Morrissey; Katherine Bond; Stephen Guy; Monica A Slavin; Claire Dendle

doi:10.1111/imj.16064

Survey of treatment practices for immunocompromised patients with COVID-19 in Australasia

Intern Med J. 2023 Apr;53(4):619-624. doi: 10.1111/imj.16064. Epub 2023 Apr 3.

Authors

Michael A Moso^{1

2

3}, Joe Sasadeusz^{1

3}, Catherine O Morrissey⁴, Katherine Bond^{2

5}, Stephen Guy^{6

7}, Monica A Slavin^{1

8

9}, Claire Dendle^{10

11}

Affiliations

¹ Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
² Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
³ Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
⁴ Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
⁵ Department of Microbiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁶ Department of Infectious Diseases, Eastern Health, Melbourne, Victoria, Australia.
⁷ Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
⁸ Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
⁹ National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹⁰ Monash Infectious Diseases, Monash Health, Victoria, Melbourne, Australia.
¹¹ School of Clinical Sciences, Monash University, Victoria, Melbourne, Australia.

PMID: 36929677
DOI: 10.1111/imj.16064

Abstract

Coronavirus disease 2019 (COVID-19) in immunocompromised patients can lead to severe and prolonged illness. Data are limited with regard to management of COVID-19 in this setting, particularly in persistent or recrudescent infection. The authors conducted an online survey among infectious diseases doctors to determine current approaches to treatment across Australasia. There was marked variability in responses relating to the diagnostic modalities and use of antiviral agents in patients with immunocompromise, highlighting the need for high-quality studies to guide treatment decisions in this group.

Keywords: COVID-19; antivirals; immunocompromised; malignancy; survey; transplant.

MeSH terms

Antiviral Agents / therapeutic use
Australasia / epidemiology
COVID-19*
Humans
Immunocompromised Host
Surveys and Questionnaires

Substances

Antiviral Agents